Shares of the vaccine maker Moderna gained traction recently due to its updates of its vaccine trials with bang up results.

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

US health officials have approved vaccines for respiratory syncytial virus (RSV), an infection that can be deadly for some ...

The CDC lowered the age for the pneumonia vaccination from 65 to 50 and recommended an extra COVID shot to some people.

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The trials for Moderna's mRESVIA vaccine, which uses the same mRNA technology as the company's Covid-19 shot, did not show any reports of GBS. In June 2023, the ACIP recommended RSV vaccination ...

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...

There is also its RSV vaccine, approved earlier this year ... in melanoma — studies suggest patients given Keytruda plus mRNA-4157 were 49% less likely to relapse or die than those who received ...

The inability of COVID vaccines to reach the long-lived plasma cell compartment in the bone marrow may explain their waning ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...